REVIEW
Add like
Add dislike
Add to saved papers

Onychomatricoma.

BACKGROUND: Onychomatricoma is a rare benign tumor originating in the nail matrix. Only eight cases have been reported until now.

OBJECTIVE: The clinical and histopathological features of this recently reported tumor will be described and its differential diagnoses outlined. A typical case of onychomatricoma is described in a 62-year-old white man.

RESULTS: Clinically, onychomatricoma is characterized by: 1) a yellowish discoloration of a longitudinal segment of the nail plate with small splinter hemorrhages within the proximal portion of the nail; 2) a thickening with increased transversal curvature of the involved nail plate positively corresponding with the yellow discoloration; and 3) a matrix tumor consisting of multiple fine filiform projections that extend into the thickened nail plate. The treatment of onychomatricoma is complete excision of the tumor.

CONCLUSION: Onychomatricoma is a new entity with clinical and histopathological features that are characteristic enough to make the correct diagnosis.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app